Lundbeck and Intomics to accelerate drug discovery
Lundbeck gains access to the advanced data-mining services provided by Intomics
Danish pharmaceutical company Lundbeck has gained access to Intomics’ expertise within bioinformatics and systems biology.
Under a collaboration agreed this week, Intomics, also based in Denmark, will assist Lundbeck, which is focused on developing drugs for treating central nervous system disorders, with methods and tools for analysing and integrating the large quantities of biological data generated in the drug development process. Financial terms were not disclosed.
‘With our data analysis capabilities and Lundbeck’s expertise in the central nervous system area, we see a great synergy that has the potential to benefit patients with CNS related disorders,’ said Thomas Jensen, chief executive of Intomics.
Intomics has expertise in biomedical analysis and mining, bioinformatics, and systems biology. Using advanced data mining technologies, the company provides tailored solutions, which it says lead to increased success rates and cost savings in pharmaceutical research projects.
